Speaker Profile
Ph.D., Distinguished Engineer, Genentech
Biography
As a Distinguished Engineer and Uber Tech Lead at Genentech, Hugo Lam am part of the leadership team leading the organization in harnessing advanced data engineering and AI to drive scientific innovation. Dr. Lam's work focuses on building scalable, FAIR-compliant data ecosystems and fostering cross-functional collaboration to accelerate discovery and informed decision-making across the enterprise.Previously, Dr. Lam founded and led HypaHub, where I directed bioinformatics and software development initiatives aimed at AI- and data-driven diagnostics and therapeutics. Under my leadership, HypaHub became a leading biomedical startup recognized by Angels, VCs, and Y Combinator. Over five years, I oversaw product development and RD, pushing the frontiers of computational medicine.Dr. Lam's tenure earlier at Roche laid the groundwork for an innovative approach to healthcare product development through informatics research and data science, including work published in Nature Communications. We championed teamwork and effective communication, ensuring our discoveries in genomic data analysis translated into real-world applications, improving lives and shaping the future of precision medicine.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, University of Pittsburgh
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions – Transforming Tumor Genomics into Therapy Guidance
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, University of Pennsylvania
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• Christopher Lieu, University of Colorado
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
• Arul M. Chinnaiyan, University of Michigan
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, ThermoFisher
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
